Your browser doesn't support javascript.
loading
Successful Reversal of Refractory Posttransplant Thrombotic Microangiopathy with Eculizumab.
Chaudhary, Satish; Sharma, Reetesh; Gupta, Saumya; Paikra, Sita; Gupta, Mohit; Upadhyay, Bal K; Sharma, Alok; Sethia, Rajiv K.
  • Chaudhary S; Department of Nephrology and Kidney Transplant Medicine, Asian Institute of Medical Sciences, Faridabad, India.
  • Sharma R; Department of Nephrology and Kidney Transplant Medicine, Asian Institute of Medical Sciences, Faridabad, India.
  • Gupta S; Department of Nephrology and Kidney Transplant Medicine, Asian Institute of Medical Sciences, Faridabad, India.
  • Paikra S; Department of Nephrology and Kidney Transplant Medicine, Asian Institute of Medical Sciences, Faridabad, India.
  • Gupta M; Department of Nephrology and Kidney Transplant Medicine, Asian Institute of Medical Sciences, Faridabad, India.
  • Upadhyay BK; Department of Nephrology and Kidney Transplant Medicine, Asian Institute of Medical Sciences, Faridabad, India.
  • Sharma A; Nephrology and Kidney Transplant Medicine, Dr. Lalpathlabs National Reference Laboratories, New Delhi, India.
  • Sethia RK; Department of Nephrology and Kidney Transplant Medicine, Asian Institute of Medical Sciences, Faridabad, India.
Indian J Nephrol ; 34(2): 191-194, 2024.
Article en En | MEDLINE | ID: mdl-38681007
ABSTRACT
Posttransplant thrombotic microangiopathy (PT-TMA) can be caused by calcineurin inhibitors (CNIs), ischemic injury, infections, or antibody-mediated rejection (ABMR). Delayed recognition can result in allograft loss. We describe the first reported case of successful reversal of refractory PT-TMA with eculizumab in India. It highlights the importance of prompt diagnosis and benefit from an early initiation of eculizumab therapy in refractory cases.
Palabras clave